Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis (Xolair CRS)

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Ellen Dutta, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01066104
First received: February 8, 2010
Last updated: September 23, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)